J9039 HCPCS code: Injection, blinatumomab, 1 microgram

J9039 is the HCPCS Level II code for injection, blinatumomab, 1 microgram. In 2024 Medicare paid an average of $116.23 per service for J9039 across 51,142 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 280 per day on DME suppliers. Medicare volume rose 226% from 2022 to 2024 (15,708 to 51,142 services). In 2024, 54 suppliers billed Medicare for J9039 (purchases), serving 97 beneficiaries; Pennsylvania, California, Maryland accounted for 36% of services.

Code details

FieldValue
SectionJ codes — Drugs administered other than oral method
Coverage codeC — Carrier judgment
Pricing indicator51 — Drug or biological (priced per ASP/average sales price rules)
BETOS categoryO1D — Chemotherapy
Added2016-01-01
Last action effective2016-01-01

Who bills J9039 (2024)

MeasureValue
Suppliers billing rentals—
Suppliers billing purchases54
Referring clinicians104
Medicare beneficiaries97
States with claims20
Share of services in top 3 states (Pennsylvania, California, Maryland)36%
YearSuppliersBeneficiaries
20224674
202348104
20245497

Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.

Medicare utilization for J9039, 2022–2024

YearServicesBeneficiariesAvg. allowedAvg. paid
202215,70818$126.72$101.08
202344,22431$123.87$99.02
202451,14230$144.94$116.23

NCCI unit limits (MUE)

Claim typeMax units per dayRationale
DME suppliers280Clinical: Data
outpatient hospital claims210Prescribing Information
practitioner claims210Prescribing Information

Medicare policy articles for this code

Covered diagnoses (460 ICD-10-CM codes)

The diagnoses most often listed as covered in the policy articles above:

ICD-10-CMDiagnosisArticles listing it
C91.00Acute lymphoblastic leukemia not having achieved remission1
C91.01Acute lymphoblastic leukemia, in remission1
C91.02Acute lymphoblastic leukemia, in relapse1
D80.0Hereditary hypogammaglobulinemia1
D80.2Selective deficiency of immunoglobulin A [IgA]1
D80.3Selective deficiency of immunoglobulin G [IgG] subclasses1
D80.4Selective deficiency of immunoglobulin M [IgM]1
D80.5Immunodeficiency with increased immunoglobulin M [IgM]1
D80.6Antibody deficiency with near-normal immunoglobulins or with hyperimmunoglobulinemia1
D80.7Transient hypogammaglobulinemia of infancy1

Showing 10 of 460. The full list, non-covered diagnoses and CSV export are in Caduvo.

What changed for J9039

Frequently asked questions

What is HCPCS code J9039?

J9039 is the HCPCS Level II code for injection, blinatumomab, 1 microgram. Short descriptor: "Injection, blinatumomab".

How much does Medicare pay for J9039?

In 2024, the average Medicare payment was $116.23 per service (average allowed $144.94).

Does Medicare cover J9039?

Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.

Which diagnoses support coverage for J9039?

Medicare policy articles that cite J9039 list 460 covered ICD-10-CM diagnosis codes across 1 article. The most cited include C91.00 (Acute lymphoblastic leukemia not having achieved remission), C91.01 (Acute lymphoblastic leukemia, in remission), C91.02 (Acute lymphoblastic leukemia, in relapse). A listed diagnosis is necessary but not sufficient; the policy's other criteria still apply.

How many units of J9039 can be billed per day?

280 on DME suppliers; 210 on outpatient hospital claims; 210 on practitioner claims (NCCI medically unlikely edits).

Related J90 codes

Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.

Next steps

Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.

All J codes · HCPCS lookup